Literature DB >> 29285509

Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists-what will REWIND add?

Keith C Ferdinand1, Indrajeet Mahata1.   

Abstract

Entities:  

Year:  2017        PMID: 29285509      PMCID: PMC5733310          DOI: 10.21037/atm.2017.10.24

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  20 in total

1.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

3.  Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.

Authors:  George G Sokos; Lazaros A Nikolaidis; Sunil Mankad; Dariush Elahi; Richard P Shannon
Journal:  J Card Fail       Date:  2006-12       Impact factor: 5.712

4.  Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation.

Authors:  Simon de Denus; Eileen O'Meara; Akshay S Desai; Brian Claggett; Eldrin F Lewis; Grégoire Leclair; Martin Jutras; Joël Lavoie; Scott D Solomon; Bertram Pitt; Marc A Pfeffer; Jean L Rouleau
Journal:  N Engl J Med       Date:  2017-04-27       Impact factor: 91.245

5.  Excess Mortality among Persons with Type 2 Diabetes.

Authors:  Mauro Tancredi; Annika Rosengren; Ann-Marie Svensson; Mikhail Kosiborod; Aldina Pivodic; Soffia Gudbjörnsdottir; Hans Wedel; Mark Clements; Sofia Dahlqvist; Marcus Lind
Journal:  N Engl J Med       Date:  2015-10-29       Impact factor: 91.245

6.  Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Rury R Holman; M Angelyn Bethel; Robert J Mentz; Vivian P Thompson; Yuliya Lokhnygina; John B Buse; Juliana C Chan; Jasmine Choi; Stephanie M Gustavson; Nayyar Iqbal; Aldo P Maggioni; Steven P Marso; Peter Öhman; Neha J Pagidipati; Neil Poulter; Ambady Ramachandran; Bernard Zinman; Adrian F Hernandez
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

Review 7.  Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.

Authors:  Francesco Paneni; Thomas F Lüscher
Journal:  Am J Med       Date:  2017-06       Impact factor: 4.965

8.  Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.

Authors:  Keith C Ferdinand; William B White; David A Calhoun; Eva M Lonn; Philip T Sager; Rocco Brunelle; Honghua H Jiang; Rebecca J Threlkeld; Kenneth E Robertson; Mary Jane Geiger
Journal:  Hypertension       Date:  2014-06-30       Impact factor: 10.190

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079

View more
  1 in total

Review 1.  Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force.

Authors:  Sanjay Kalra; Ashok Kumar Das; Rakesh Kumar Sahay; Manash Pratim Baruah; Mangesh Tiwaskar; Sambit Das; Sudip Chatterjee; Banshi Saboo; Ganapathi Bantwal; Saptarshi Bhattacharya; Gagan Priya; Manoj Chawla; Kiraninder Brar; Syed Abbas Raza; Azizul Hasan Aamir; Dina Shrestha; Noel Somasundaram; Prasad Katulanda; Faria Afsana; Shahjada Selim; Mohammad Wali Naseri; Ali Latheef; Manilka Sumanatilleke
Journal:  Diabetes Ther       Date:  2019-07-29       Impact factor: 2.945

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.